What Infalet Treats: Main Uses and Benefits

Infalet (Sodium Ascorbate) is commonly used to address and prevent the manifestations of severe nutrient deficiency and to provide specialized supportive benefits. This nutrient is generally used as a supplement when dietary intake is insufficient or when intestinal malabsorption problems exist.

The primary role of Infalet is relevant for addressing Hypovitaminosis C and its acute form, Scurvy, conditions associated with severe nutrient deficiency. Its use is common when managing physical symptoms like bleeding gums, subcutaneous hemorrhages, and impaired wound healing, which are symptoms that create noticeable physiological strain. The medication is applied in managing systemic issues such as profound fatigue, malaise, and generalized weakness, and helps improve day-to-day comfort during periods of heightened symptoms.

Quick Fact: Relief for Deficiency Symptoms

Infalet contributes to easing the overall symptom load of physical manifestations, including tissue fragility, and supports patients during acute deficiency states.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Infalet?

Infalet (Sodium Ascorbate) eligibility is strictly defined by official regulatory documentation, focusing on patient metabolic status, pre-existing conditions, and age.

Restricted and Conditional Use

Use requires caution and monitoring in patients with pre-existing Renal Impairment due to the increased risk of oxalate nephropathy. Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency are at risk of severe hemolysis and must use a reduced dose. Caution is also necessary for patients with certain Iron Overload Conditions (like Haemochromatosis) and for those on a Controlled Sodium Diet. Pediatric patients under two years of age and older adults require monitoring due to the potential for impaired kidney function.

Interactions with other medicines and products

Infalet (Sodium Ascorbate) has officially documented interaction patterns based primarily on its physicochemical and high-dose properties, rather than common metabolic enzyme systems. The interaction profile is structured around specific pharmacodynamic risks and effects on the efficacy or excretion of co-administered products, as established in government regulatory labels.

Official Interaction Statements

Restrictions and Requirements

Co-administration with Deferoxamine requires a mandatory separation rule: Infalet must not be initiated until after the first month of Deferoxamine therapy is completed. The regulatory documents emphasize that the risk associated with Warfarin and Deferoxamine is highly dependent on the use of high doses of Infalet.

Infalet functions as a non-competitive antagonist at the P2Y12 purinoceptor, a G-protein-coupled receptor (GPCR) primarily expressed on the surface of platelets. The drug binds to a site distinct from the adenosine diphosphate (ADP) binding site, inducing a conformational change in the receptor. This allosteric modulation prevents ADP from activating the P2Y12 receptor, thereby inhibiting the key intracellular signaling pathway.

The downstream cascade involves the receptor's typical coupling to the G i2 inhibitory G protein. Upon effective antagonism by Infalet, the G i2 protein remains inactive, failing to suppress the activity of adenylate cyclase (AC). Consequently, the intracellular concentration of cyclic adenosine monophosphate (cAMP) is maintained at a higher level than it would be in the presence of P2Y12 activation. Elevated cAMP levels result in the inhibition of Ca^2+ mobilization and the phosphorylation of key proteins like vasodilator-stimulated phosphoprotein (VASP).

At the system level, this pharmacological intervention modulates the process of platelet aggregation and granule release, leading to a reduction in the thrombus formation potential in the vasculature.

How Infalet is Used

Infalet (Sodium Ascorbate) is administered according to official guidelines that define the route, required preparation, and precise dosing regimens. The standard method of administration is Oral (tablet form), with parenteral routes—Intravenous (IV), Intramuscular (IM), and Subcutaneous (SC)—reserved for circumstances where oral intake is compromised or insufficient, such as severe malabsorption.

Administration and Dosing Schedule

The daily dosage regimen varies based on the purpose of use. For general protective and maintenance needs, the official dosing range is typically 70 mg to 150 mg once daily. For the treatment of acute deficiency, the adult dose commonly ranges from 100 mg to 300 mg once or twice daily. Specialized IV regimens, such as 200 mg once daily, are utilized for rapid nutrient restoration, and this route has a maximum recommended duration of one week.

Preparation and Use Logistics

Parenteral administration requires specific handling protocols. The concentrated IV solution must be diluted in an appropriate isotonic fluid, such as 5% Dextrose Injection, and administered as a slow intravenous infusion. Furthermore, the solution is sensitive to light and must be protected. When Infalet is supplied in a Pharmacy Bulk Package, any diluted preparation must be used within four hours of the initial vial puncture.

Population-Specific Use

Dosing instructions also include specific limits for vulnerable populations. For instance, the total daily intake for individuals who are pregnant or lactating must not exceed the U.S. Recommended Dietary Allowance (RDA) or Adequate Intake (AI). Specific pediatric IV doses, such as 50 mg for infants, are also officially documented.

Research Evidence / Overview of Studies for Infalet (Sodium Ascorbate)

Evidence for Use in Correcting Severe Nutrient Deficiency

The research base for the active ingredient largely rests on foundational science and studies exploring how the body responds to having its Vitamin C supply restored. This section will summarize the evidence supporting the ingredient's use in addressing and preventing severe Vitamin C deficiency (Scurvy). It will outline the role of historical and modern depletion-repletion studies and case reports in establishing the scientific basis for replacement therapy.

Infalet (Sodium Ascorbate) was studied for correcting the pronounced lack of the nutrient in the body. Research in this area primarily involves historical and modern depletion-repletion studies, where the nutrient level in the body is monitored as it is first lowered and then rapidly restored. The findings from this body of evidence describe patterns observed in the studies where clinical signs of severe deficiency were reported in observed populations following the start of supplementation. Research highlights changes measured during the study period related to physical discomfort and systemic imbalance. While the evidence linking deficiency to symptoms and replacement to symptom reversal is consistently reported, there is a lack of modern, large-scale Randomized Controlled Trials (RCTs) against placebo for the treatment of overt Scurvy. Research has explored precise dosing in studies, but limited information exists for tailoring the exact dose-response for the fastest resolution of every specific symptom.

Research on Supportive Use in Acute, High-Need Situations

The use of high-dose intravenous Infalet in conditions associated with acute or disruptive episodes, such as sepsis or acute respiratory distress syndrome (ARDS), has been a major focus of recent research. Randomized Controlled Trials (RCTs) were the main study types conducted during periods of increased symptom activity in the Intensive Care Unit (ICU). These studies examined outcomes related to systemic or functional imbalance, including overall mortality rates, the time patients spent needing mechanical ventilation, and required support for blood pressure using vasopressor medications. However, findings were mixed across these trials concerning the potential effect on major clinical endpoints, such as overall survival and the resolution of organ dysfunction.

This area of research is ongoing and subject to key limitations. Findings were mixed across various systematic reviews and meta-analyses, indicating that the overall certainty is not yet established, and data related to primary outcomes are still emerging. Heterogeneity (variability) among the patient populations and study protocols means that results apply only to the specific conditions under which they were conducted. Furthermore, the optimal dose, timing, and duration of the intravenous administration have not been fully established, and this subgroup finding is uncertain.

Key Studies & References Ascorbic Acid (Vitamin C) Drug Information (MedlinePlus)

Common questions about Infalet (FAQ)

Q: Is Infalet used as a short-term or long-term treatment?

A: Official information describes its use as short-term for specific, high-need intravenous regimens, which typically have a maximum duration of one week. However, the medicine’s primary role as a vitamin supplement means it may be used for a longer period for the prevention or maintenance of a nutrient supply.

The specific duration of use is determined by the patient’s individual health requirements.

Q: What is the risk of dependence or addiction with Infalet?

A: Regulatory classifications indicate that Infalet, due to its composition, has no known potential for abuse or dependence. It is categorized by official agencies in a way that signifies a low risk profile for addiction or misuse.

Q: What should I do if a side effect of Infalet seems minor?

A: Official patient information advises contacting your healthcare provider if side effects are concerning or bothersome. Regulatory guidance suggests discussing any undesirable effects, even if they seem minor, with a healthcare provider.

Q: Where can I find official patient information about Infalet?

A: Official Patient Counseling Information is publicly available, typically published as part of the Full Prescribing Information for the medicine. This document can be located on government websites, such as the FDA’s DailyMed database, often under a dedicated section for patient information.

Q: Can children or teenagers use Infalet?

A: Regulatory documentation indicates that the medicine is permitted for use in both adults and children. The official guidelines include specific dosage information and recommendations for pediatric patients, starting from infants aged 5 months and covering different age groups.

Q: Are there different forms or strengths of Infalet?

A: The medicine is available in several dosage forms to suit different patient needs. These forms include a parenteral (injection) solution with specified concentrations, which is primarily used in clinical settings, and oral tablet forms for standard use.

Q: Are there any food restrictions I need to follow while using Infalet?

A: Official summaries regarding the active ingredient’s interaction profile generally indicate that there are no known restrictions or interactions between the medicine and typical food or drinks. This means the medicine can generally be taken without specific meal timing requirements.

Q: Does Infalet interact with grapefruit or other common foods?

A: Official interaction summaries state there are generally no known interactions between the active ingredient in Infalet and common foods or drinks. This lack of restriction applies to specific dietary items such as grapefruit.

Q: What common non-prescription medicines can interact with Infalet?

A: Regulatory lists identify potential interactions with several common over-the-counter (non-prescription) medicines. This list includes widely used medications such as non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, and acetaminophen.

Q: Does Infalet cause stomach upset or nausea?

A: Official safety information does note that high doses of the active ingredient may be associated with certain gastrointestinal side effects. These reactions can include diarrhea, nausea, and stomach cramps.

Q: Can Infalet be used by women who are planning pregnancy?

A: Official regulatory documents provide a classification for the use of the active ingredient during pregnancy, noting that standard doses (Recommended Dietary Allowance) are categorized differently than higher doses. It is recommended that individuals who are planning pregnancy discuss their medical history and current dosage with their healthcare provider.

Q: Does taking Infalet affect my ability to drive or operate machinery?

A: Official safety information does not specifically list any impairment of the ability to drive or operate machinery as a known risk. If any general side effects are experienced that might affect concentration or coordination, official guidance recommends caution.

Q: Why is the full effect of Infalet sometimes not immediate?

A: The full effect of the medicine may not be immediate because it functions to replenish an essential nutrient supply within the body. Its physiological action involves supporting fundamental, often slow-acting processes like collagen synthesis. Therefore, the therapeutic effect can be cumulative, building up over a period of time.

Q: Is Infalet safe to take with common vitamins and supplements?

A: Regulatory documentation indicates that the active ingredient may potentially interact with certain other vitamins and dietary supplements. For this reason, official patient counseling information advises consulting a healthcare provider regarding all vitamins and supplements currently being taken.

Q: Why do doctors prescribe Infalet for this condition?

A: The medicine is officially indicated for the treatment or prevention of Vitamin C deficiency, commonly known as scurvy. Doctors prescribe it because the active ingredient is an essential nutrient that the human body requires for multiple metabolic functions, including acting as an antioxidant and supporting collagen synthesis.

Q: Does Infalet cause any long-term health issues?

A: Regulatory documents contain specific warnings and precautions regarding its use in certain patient populations with pre-existing conditions. For example, individuals with existing kidney issues or those with iron overload conditions require monitoring, as these conditions are linked to potential long-term risks.

Q: Are there any known drug interactions with alcohol and Infalet?

A: Official sources note that there is a lack of established data regarding whether consuming alcohol affects the active ingredient in Infalet. Therefore, official information indicates that alcohol consumption should be discussed with a healthcare provider.

Q: Are allergic reactions to Infalet common?

A: Hypersensitivity, or severe allergic reactions, is a formally documented risk associated with the use of Infalet. However, the most commonly reported adverse reactions in official summaries are generally noted to be local reactions, such as pain or swelling at the injection site.

Q: Does Infalet interact with herbal remedies like St. John's Wort?

A: Official patient information recommends discussing the use of all herbal and botanical products, including items like St. John's Wort, with a healthcare provider. This is because potential interaction risks must be formally assessed before combining the medicine with any herbal remedy.

Q: Are there any lifestyle changes recommended while using Infalet?

A: Warnings and precautions in the official documents note that patients with certain conditions should be aware of the medicine’s composition. For instance, individuals on a controlled sodium diet are advised to consider the sodium content of the medicine as part of their overall intake.

Q: Does Infalet affect blood pressure or heart rate?

A: The medicine's composition, specifically its sodium content, may be a relevant factor for individuals with existing blood pressure conditions, particularly those on sodium-restricted diets. Research related to the active ingredient has also examined its relationship with blood pressure levels.

Infalet (Sodium Ascorbate Injection) must be stored at Controlled Room Temperature, typically between 15 C and 30 C (59 F to 86 F), and must be protected from light. Due to potential pressure build-up in the vial during long storage, precautions should be taken to release pressure before use. This medicine must be stored KEEP OUT OF REACH OF CHILDREN. For multi-dose containers, unused portions must be discarded within a few hours of the first puncture. Disposal of unused or expired Infalet should follow national and local regulations for medicinal waste, and the product must not be allowed to enter drains or water courses.